sponsored

Imagine a healthcare system made up of multiple AI agents: one that manages symptom assessment, another scheduling, a third insurance, and a fourth pharmacy. Each is an expert in its domain. But they all have their own distinct knowledge and objectives. Today they can exchange data, but they are not

Drug discovery is a high-cost, high-risk endeavor that is under growing pressure from a market increasingly defined by first-mover advantage. Since the 1950s, the cost of developing new pharmaceuticals has roughly doubled every nine years—a phenomenon known as Eroom’s Law. Today, bringing a new drug

For the enterprise, the promise of agentic AI is much more than just a better chatbot. It is software agents that execute business tasks end-to-end across people, business workflows, data, and systems. The platform best-suited to run agents is built with proper CPU capacity, resilient data access, p

Designing and developing a new medicine is an expensive, failure-prone scientific challenge. A new drug can take many years to develop, at the cost of a significant investment. And even then, most possible candidates never reach the patient. For biologic medicines, therapies made from engineered pro

有关人工智能的讨论通常集中在算法、计算能力或对新半导体制造工厂和超大规模数据中心的巨额投资上。但在每一项进步的背后，还有使它们成为可能的另一层创新：先进材料。每一代新一代人工智能